首页> 美国卫生研究院文献>other >Priming with Recombinant Auxotrophic BCG Expressing HIV-1 Gag RT and Gp120 and Boosting with Recombinant MVA Induces a Robust T Cell Response in Mice
【2h】

Priming with Recombinant Auxotrophic BCG Expressing HIV-1 Gag RT and Gp120 and Boosting with Recombinant MVA Induces a Robust T Cell Response in Mice

机译:用表达HIV-1 GagRT和Gp120的重组营养缺陷型BCG引发和用重组MVA增强诱导小鼠的强健T细胞反应。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

In previous studies we have shown that a pantothenate auxotroph of Myocbacterium bovis BCG (BCGΔpanCD) expressing HIV-1 subtype C Gag induced Gag-specific immune responses in mice and Chacma baboons after prime-boost immunization in combination with matched rMVA and VLP vaccines respectively. In this study recombinant BCG (rBCG) expressing HIV-1 subtype C reverse transcriptase and a truncated envelope were constructed using both the wild type BCG Pasteur strain as a vector and the pantothenate auxotroph. Mice were primed with rBCG expressing Gag and RT and boosted with a recombinant MVA, expressing a polyprotein of Gag, RT, Tat and Nef (SAAVI MVA-C). Priming with rBCGΔpanCD expressing Gag or RT rather than the wild type rBCG expressing Gag or RT resulted in higher frequencies of total HIV-specific CD8+ T cells and increased numbers of T cells specific to the subdominant Gag and RT epitopes. Increasing the dose of rBCG from 105 cfu to 107 cfu also led to an increase in the frequency of responses to subdominant HIV epitopes. A mix of the individual rBCGΔpanCD vaccines expressing either Gag, RT or the truncated Env primed the immune system for a boost with SAAVI MVA-C and generated five-fold higher numbers of HIV-specific IFN-γ-spot forming cells than mice primed with rBCGΔpanCD containing an empty vector control. Priming with the individual rBCGΔpanCD vaccines or the mix and boosting with SAAVI MVA-C also resulted in the generation of HIV-specific CD4+ and CD8+ T cells producing IFN-γ and TNF-α and CD4+ cells producing IL-2. The rBCG vaccines tested in this study were able to prime the immune system for a boost with rMVA expressing matching antigens, inducing robust, HIV-specific T cell responses to both dominant and subdominant epitopes in the individual proteins when used as individual vaccines or in a mix.
机译:在先前的研究中,我们表明,表达初生免疫后,表达HIV-1 C型Gag的HIV-1亚型C Gag的牛分枝杆菌BCG(BCGΔpanCD)的泛营养缺陷型诱导了Gag特异性免疫反应,分别与匹配的rMVA和VLP疫苗组合。在这项研究中,使用野生型BCG巴斯德菌株作为载体和泛酸营养缺陷型,构建了表达HIV-1亚型C反转录酶和截短包膜的重组BCG(rBCG)。小鼠用表达Gag和RT的rBCG引发,并用表达Gag,RT,Tat和Nef的多蛋白的重组MVA(SAAVI MVA-C)加强免疫。用表达Gag或RT的rBCGΔpanCD而不是表达Gag或RT的野生型rBCG引发,导致总的HIV特异性CD8 + T细胞的频率更高,并且对主要Gag和RT特异性的T细胞数量增加表位。 rBCG剂量从10 5 cfu增加到10 7 cfu也导致对主要HIV表位的反应频率增加。表达Gag,RT或截短的Env的单个rBCGΔpanCD疫苗的混合物用SAAVI MVA-C增强了免疫系统的免疫力,产生的HIV特异性IFN-γ斑点形成细胞的数量是用AVI激活的小鼠的五倍rBCGΔpanCD包含空载体对照。用单个rBCGΔpanCD疫苗或混合疫苗初次接种并用SAAVI MVA-C加强免疫也可产生HIV特异性CD4 + 和CD8 + T细胞,产生IFN-γ产生IL-2的TNF-α和CD4 + 细胞。在这项研究中测试的rBCG疫苗能够通过表达匹配抗原的rMVA来增强免疫系统的免疫力,当用作单独的疫苗或在疫苗中使用时,对单个蛋白中的显性和显性表位均产生强烈的HIV特异性T细胞反应。混合。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号